

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

Cancer Dependency Map Portal

RRID:SCR_017655

Type: Tool

Proper Citation

Cancer Dependency Map Portal (RRID:SCR_017655)

Resource Information

URL: <https://depmap.org/portal/>

Proper Citation: Cancer Dependency Map Portal (RRID:SCR_017655)

Description: Portal for identifying genetic and pharmacologic dependencies and biomarkers that predicts them by providing access to datasets, visualizations, and analysis tools that are being used by Cancer Dependency Map Project at Broad Institute. Project to systematically identify genes and small molecule dependencies and to determine markers that predict sensitivity. All data generated by DepMap Project are available to public under CC BY 4.0 license on quarterly basis and pre-publication.

Abbreviations: DepMap Portal

Synonyms: Dependency Map Portal, Dependency Map portal, Cancer DepMap, Cancer Dependency Map Project

Resource Type: catalog, data or information resource, data set, database, portal, project portal

Keywords: Cancer, vulnerability, dataset, visualization, analysis, tool, catalog, biomarker, genetic, drug, sensitivity, tumor, model, FASEB list

Availability: Free, Available for download, Freely available

Resource Name: Cancer Dependency Map Portal

Resource ID: SCR_017655

Record Creation Time: 20220129T080336+0000

Record Last Update: 20260829T182548+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Dependency Map Portal.

No alerts have been found for Cancer Dependency Map Portal.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1417 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kim M, et al. (2026) Elimusertib, a Novel ATR Inhibitor, Induces Anti-tumor Effects through Replication Catastrophe in Breast Cancers. Cancer research and treatment, 58(1), 159.

Picard M, et al. (2026) Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value. Journal for immunotherapy of cancer, 14(2).

Zhang W, et al. (2026) XMD8-92 and JWG-045 exhibit anti-ferroptotic activities, independently of inhibiting ERK5. Scientific reports, 16(1).

Chakraborty K, et al. (2026) Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma. Cell death & disease, 17(1), 190.

Wang Y, et al. (2026) Machine Learning-Based Analysis of Large-Scale Transcriptomic Data Identifies Core Genes Associated with Multi-Drug Resistance. International journal of molecular sciences, 27(3).

Li G, et al. (2026) NeuroD1-USP1-MYCN axis drives tumor progression in neuroblastoma. Journal of translational medicine, 24(1).

Li D, et al. (2026) SNRPD2-dependency Fuels an Oncogenic Alternative Splicing Repertoire Driving Disease Aggressiveness in Glioma. Cancer genomics & proteomics, 23(2), 169.

Kumar S, et al. (2026) Pan-cancer analysis reveals differential PERK expression across tumour types and its potential as a therapeutic target. Discover oncology, 17(1).

Cooper J, et al. (2026) A guide to selecting high-performing antibodies for Alpha-1-antitrypsin (UniProt ID: P01009) for use in western blot, immunoprecipitation and flow cytometry. F1000Research, 15, 73.

Page PM, et al. (2026) Kidney-specific HIF-1?-dependent ARL10/miR-1271-5p overexpression in clear cell renal cell carcinoma. British journal of cancer, 135(2), 189.

Zhao Y, et al. (2026) Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13. *Frontiers in immunology*, 17, 1691436.

Reveron-Thornton RF, et al. (2026) A Pan-Cancer Single-Cell Atlas to Evaluate Tumor Identity, Cell Line Concordance, and Dependency Mapping. *bioRxiv : the preprint server for biology*.

Rice K, et al. (2026) Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A). *Journal of molecular medicine (Berlin, Germany)*, 104(1).

Wang J, et al. (2026) Integrative multi-omics analysis-based Mendelian randomization identifies association of DNA repair-related genes with oral cancer. *Cancer biomarkers : section A of Disease markers*, 43, 18758592261455209.

Murr J, et al. (2026) The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. *MedComm*, 7(6), e70794.

Rezola Artero M, et al. (2026) Intracellular complement Factor H promotes tumor progression through modulation of cell cycle and actin cytoskeleton. *Communications biology*, 9(1).

Yun HJ, et al. (2026) CEBPB Expression in Tumor Cells Drives Immune Evasion in Colorectal Cancer via CTLA4 Up-regulation in T Cells. *Cancer communications (London, England)*, 46, 0013.

Meeson KE, et al. (2026) Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer. *Cancer & metabolism*, 14(1).

Liu Z, et al. (2026) Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer. *Signal transduction and targeted therapy*, 11(1).

Tuncal A, et al. (2026) Integrative In Silico Identification of TP53-Associated Drug Repurposing Candidates in Lung Adenocarcinoma. *Pharmaceuticals (Basel, Switzerland)*, 19(5).